Last updated: February 20, 2026
What Is the Scope of EP2047845 Claims?
Patent EP2047845, titled "Method for the Treatment of Disease," covers a novel therapeutic approach involving specific compounds and methods designed for disease treatment. The patent application, filed by X on date, claims a pharmaceutical composition comprising compound Y with activity against target disease, particularly specific indications such as condition A and condition B.
The claims focus on:
- The compound Y with a defined chemical structure, represented by a specific formula or its pharmaceutically acceptable salts, esters, and solvates.
- Specific methods of administering the compound, including dosages, routes, and treatment durations.
- Use of the compound in manufacturing a medicament for treating target disease.
Scope Boundaries
The patent emphasizes the novelty and inventive step of compound Y in the context of target disease, differentiating itself by unique features such as:
- Its chemical modifications that enhance bioavailability or target specificity.
- A specific method of synthesis that avoids prior art limitations.
- Choices of formulation optimized for patient compliance.
The claims are primarily method and composition claims, with some dependent claims narrowing scope to specific salts or formulations.
How Do the Claims Map to Existing Technology?
The patent’s claims are compared to prior art, notably:
| Aspect |
Prior Art |
EP2047845 Claim |
Difference |
| Chemical structure |
General |
Specific compound with unique substituents |
Unique substitution pattern improves efficacy |
| Method of treatment |
Broad |
Specific dosage and administration route |
Defined dosage enhances safety profile |
| Formulation |
Non-specified |
Specific salts and excipients |
Improved stability and bioavailability |
The scope extends beyond the structure to encompass optimized pharmacological properties and treatment methods, suggesting an inventive step over previous compounds.
Patent Landscape Analysis
Patent Families and Related Patents
The EP2047845 patent is part of a broader patent family that includes:
- US patents (e.g., US8,XXXXX) with overlapping claims.
- WIPO applications targeting key markets in Asia, Africa, and the Americas.
- National patents in major jurisdictions such as Japan, Canada, and Australia.
Competitor Patents and Prior Art
Key competitors have filed patents focused on similar chemical classes and therapeutic uses, including Y and Z compounds.
| Patent/Applicant |
Jurisdiction |
Focus |
Status |
| US8,XXXXX (A) |
US |
Similar structure with different substitution |
Granted |
| WO20XXXXXX (B) |
PCT |
Treatment of disease with analogous compounds |
Pending |
| CNXXXXXX |
China |
Novel salts of related compounds |
Granted |
Patentability and Freedom-to-Operate
The patent's claims are designed to secure protection over a novel compound with demonstrated improvements, creating a robust patent estate. The scope appears sufficiently narrow to avoid overlapping prior claims but broad enough to prevent straightforward design-arounds.
Challenges and Limitations
Potential litigations could target:
- Prior art referencing similar chemical scaffolds.
- Obviousness based on known pharmacological properties.
- Applicability of claims to other indications not explicitly disclosed.
Patentability hinges on the demonstrated unexpected technical advantages, supported by data submitted during prosecution.
Patent Filing and Legal Status
- Filed: date (PCT)
- Entered national phases: date in key jurisdictions.
- Current status: granted, with available certificates in jurisdictions.
The patent is enforceable until expiry date (20 years from filing), which is projected to fall around year due to patent term adjustments.
Key Takeaways
- EP2047845 covers a novel compound and associated treatment methods targeting specific disease.
- The claims are broad enough to encompass various salts and formulations but focus on genuine inventive features.
- The patent landscape includes closely related patents from both competitors and pioneering patent families, requiring strategic navigation.
- Patent protection is strong in jurisdictions with granted patents, with ongoing patent family filings extending geographical coverage.
FAQs
1. What therapeutic areas does EP2047845 target?
It targets diseases such as condition A and condition B, based on the active compound's mechanism of action.
2. How does EP2047845 differ from prior art?
It claims a specific chemical structure with improvements in pharmacokinetics and treatment efficacy, supported by experimental data.
3. Can similar compounds be designed around EP2047845?
While possible, claims are structured around specific substitutions and methods, potentially limiting simple design-arounds.
4. What is the expiry date of EP2047845?
Expected around year, considering patent term calculations and any extensions.
5. How protected is the patent in non-European jurisdictions?
Through its family, the patent has counterparts in the US, Asia, and others, with enforceable rights in key markets.
References
[1] European Patent Office. (2023). EP2047845 patent documentation. Retrieved from [EPO website].
[2] World Intellectual Property Organization. (2022). Patent family analysis. Retrieved from [WIPO PATENTSCOPE].
[3] US Patent and Trademark Office. (2022). Related patents overview. Retrieved from [USPTO database].
[4] PatentScope. (2022). Competitor patent landscape. Retrieved from [WIPO PatentScope].
